Department of Cancer Biology and Genetics, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Department of Molecular Pharmacology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Science. 2018 Dec 21;362(6421):1416-1422. doi: 10.1126/science.aas9090.
Molecularly targeted therapies aim to obstruct cell autonomous programs required for tumor growth. We show that mitogen-activated protein kinase (MAPK) and cyclin-dependent kinase 4/6 inhibitors act in combination to suppress the proliferation of KRAS-mutant lung cancer cells while simultaneously provoking a natural killer (NK) cell surveillance program leading to tumor cell death. The drug combination, but neither agent alone, promotes retinoblastoma (RB) protein-mediated cellular senescence and activation of the immunomodulatory senescence-associated secretory phenotype (SASP). SASP components tumor necrosis factor-α and intercellular adhesion molecule-1 are required for NK cell surveillance of drug-treated tumor cells, which contributes to tumor regressions and prolonged survival in a KRAS-mutant lung cancer mouse model. Therefore, molecularly targeted agents capable of inducing senescence can produce tumor control through non-cell autonomous mechanisms involving NK cell surveillance.
分子靶向治疗旨在阻断肿瘤生长所需的细胞自主程序。我们表明,丝裂原活化蛋白激酶(MAPK)和细胞周期蛋白依赖性激酶 4/6 抑制剂联合作用,抑制 KRAS 突变型肺癌细胞的增殖,同时引发自然杀伤(NK)细胞监视程序,导致肿瘤细胞死亡。药物联合治疗,但不是单独使用,可促进视网膜母细胞瘤(RB)蛋白介导的细胞衰老和免疫调节衰老相关分泌表型(SASP)的激活。SASP 成分肿瘤坏死因子-α和细胞间黏附分子-1是 NK 细胞对药物处理的肿瘤细胞进行监视所必需的,这有助于肿瘤消退,并延长 KRAS 突变型肺癌小鼠模型中的存活时间。因此,能够诱导衰老的分子靶向药物可以通过涉及 NK 细胞监视的非细胞自主机制产生肿瘤控制。